Advertisement

Identifying Prediabetes and Type 2 Diabetes in Asymptomatic Youth: Should HbA1c Be Used as a Diagnostic Approach?

  • Mary Ellen Vajravelu
  • Joyce M. LeeEmail author
Economics and Policy in Diabetes (ES Huang and AA Baig, Section Editors)
  • 437 Downloads
Part of the following topical collections:
  1. Topical Collection on Economics and Policy in Diabetes

Abstract

Purpose of Review

Because the incidence of type 2 diabetes and prediabetes in children is rising, routine screening of those at risk is recommended. In 2010, the ADA made the recommendation to include hemoglobin A1c (HbA1c) as a diagnostic test for diabetes, in addition to the oral glucose tolerance test or fasting plasma glucose. Our objective was to assess the pediatric literature with regard to HbA1c test performance and discuss advantages and disadvantages of use of the test for diagnostic purposes.

Recent Findings

HbA1c has a number of advantages, including elimination of the need for fasting, lower variability, assay standardization, and long-term association with future development of diabetes. It also has many drawbacks. It can be affected by a number of non-glycemic factors, including red blood cell turnover, hemoglobinopathies, medications, race, and age. In particular, it performs differently in children compared with adults, generally with lower sensitivity for prediabetes (as low as 0–5% in children vs 23–27% in adults) and lower area under the receiver operating characteristic curve (AUC) (0.53 vs 0.73 for prediabetes), and it has lower efficacy at a higher cost, compared with other tests of glycemia. Finally, HbA1c may perform very differently across diverse populations according to race/ethnicity; in Chinese populations, the proportion of individuals classified with prediabetes based on HbA1c predominates compared with IFG (77% for HbA1c vs 27.7% for IFG), whereas in US populations, it is the opposite (24.8% for HbA1c vs 80.1% for FPG).

Summary

HbA1c is controversial because although it is convenient, it is not a true measure of glycemia. The interpretation of HbA1c results requires a nuanced understanding that many primary care physicians who are ordering the test in greater numbers do not possess. Alternative markers of glycemia may hold promise for the future but are not yet endorsed for use in practice. Further studies are needed to determine appropriate thresholds for screening tests and the long-term impact of screening and identification.

Keywords

Diabetes Fasting plasma glucose Oral glucose tolerance test Hemoglobin A1c 

Notes

Acknowledgments

M.E. Vajravelu is supported by NIH/NIDDK training grant T32 DK007314. J.M. Lee is supported by R01 HD074559.

Compliance with Ethical Standards

Conflict of Interest

M.E. Vajravelu declares that she has no conflict of interest. J.M. Lee reports receiving consulting fees from Unitio and grant funding from Lenovo.

Human and Animal Rights and Informed Consent

This article does not contain any studies with animal subjects performed by any of the authors. With regard to the authors’ research cited in this paper, all procedures were followed in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 2000 and 2008.

References

Papers of particular interest, published recently, have been highlighted as:• Of importance•• Of outstanding importance

  1. 1.
    • Mayer-Davis EJ, Lawrence JM, Dabelea D, Divers J, Isom S, Dolan L, et al. Incidence trends of type 1 and type 2 diabetes among youths, 2002–2012. N Engl J Med. 2017;376(15):1419–29. This study highlights the rising incidence of type 2 diabetes in youth, which was greatest among minority racial and ethnic groups. CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    American Diabetes Association. Type 2 diabetes in children and adolescents. Pediatrics. 2000;105(3):671–80.CrossRefGoogle Scholar
  3. 3.
    Williams DE, Cadwell BL, Cheng YJ, Cowie CC, Gregg EW, Geiss LS, et al. Prevalence of impaired fasting glucose and its relationship with cardiovascular disease risk factors in US adolescents, 1999-2000. Pediatrics. 2005;116(5):1122–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Copeland KC, Zeitler P, Geffner M, Guandalini C, Higgins J, Hirst K, et al. Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. J Clin Endocrinol Metab. 2011;96(1):159–67.CrossRefPubMedGoogle Scholar
  5. 5.
    Savoye M, Caprio S, Dziura J, Camp A, Germain G, Summers C, et al. Reversal of early abnormalities in glucose metabolism in obese youth: results of an intensive lifestyle randomized controlled trial. Diabetes Care. 2014;37(2):317–24.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Rosenbloom AL, Joe JR, Young RS, Winter WE. Emerging epidemic of type 2 diabetes in youth. Diabetes Care. 1999;22(2):345–54.CrossRefPubMedGoogle Scholar
  7. 7.
    American Diabetes Association. Type 2 diabetes in children and adolescents.. Diabetes Care 2000;23(3):381–389.Google Scholar
  8. 8.
    American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33(Suppl 1):S62–9.CrossRefPubMedCentralGoogle Scholar
  9. 9.
    American Diabetes Association. 12. Children and adolescents: standards of medical care in diabetes—2018. Diabetes Care. 2018;41(Suppl 1):S126–S36.Google Scholar
  10. 10.
    The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus*. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997;20(7):1183–97.CrossRefGoogle Scholar
  11. 11.
    Cowie CC, Rust KF, Byrd-Holt DD, Gregg EW, Ford ES, Geiss LS, et al. Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988–2006. Diabetes Care. 2010;33(3):562–8.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Parrinello CM, Selvin E. Beyond HbA1c and glucose: the role of nontraditional glycemic markers in diabetes diagnosis, prognosis, and management. Curr Diab Rep. 2014;14(11):548.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    World Health Organization. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus: abbreviated report of a WHO consultation. 2011:1–25.Google Scholar
  14. 14.
    Selvin E, Crainiceanu CM, Brancati FL, Coresh J. Short-term variability in measures of glycemia and implications for the classification of diabetes. Arch Intern Med. 2007;167(14):1545–51.CrossRefPubMedGoogle Scholar
  15. 15.
    Colagiuri S, Lee CM, Wong TY, Balkau B, Shaw JE, Borch-Johnsen K, et al. Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes. Diabetes Care. 2011;34(1):145–50.CrossRefPubMedGoogle Scholar
  16. 16.
    •• Vijayakumar P, Nelson RG, Hanson RL, Knowler WC, Sinha M. HbA1c and the prediction of type 2 diabetes in children and adults. Diabetes Care. 2017;40(1):16–21. This study provides the first longitudinal evidence of the utility of HbA1c as a predictor of type 2 diabetes when used in American Indian youth. CrossRefPubMedGoogle Scholar
  17. 17.
    Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan D, Peterson CM, et al. Tests of glycemia in diabetes. Diabetes Care. 2004;27(7):1761–73.CrossRefPubMedGoogle Scholar
  18. 18.
    Sacks DB, John WG. Interpretation of hemoglobin A1c values. JAMA 2014;311(22):2271–2, 2272.Google Scholar
  19. 19.
    Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the pediatric Endocrine Society. Diabetes Care. 2010;33(12):2697–708.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Spencer DH, Grossman BJ, Scott MG. Red cell transfusion decreases hemoglobin A1c in patients with diabetes. Clin Chem. 2011;57(2):344–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Brooks AP, Metcalfe J, Day JL, Edwards MS. Iron deficiency and glycosylated haemoglobin A. Lancet. 1980;2(8186):141.CrossRefPubMedGoogle Scholar
  22. 22.
    Coban E, Ozdogan M, Timuragaoglu A. Effect of iron deficiency anemia on the levels of hemoglobin A1c in nondiabetic patients. Acta Haematol. 2004;112(3):126–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Hardikar PS, Joshi SM, Bhat DS, Raut DA, Katre PA, Lubree HG, et al. Spuriously high prevalence of prediabetes diagnosed by HbA(1c) in young Indians partly explained by hematological factors and iron deficiency anemia. Diabetes Care. 2012;35(4):797–802.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Arnold JG, McGowan HJ. Delay in diagnosis of diabetes mellitus due to inaccurate use of hemoglobin A1C levels. J Am Board Fam Med. 2007;20(1):93–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Little RR, Roberts WL. A review of variant hemoglobins interfering with hemoglobin A1c measurement. J Diabetes Sci Technol. 2009;3(3):446–51.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Meyer LM, Adams JG 3rd, Steinberg MH, Miller IE, Stokes N. Screening for sickle cell trait: the veterans administration National Sickle Cell Program. Am J Hematol. 1987;24(4):429–32.CrossRefPubMedGoogle Scholar
  27. 27.
    NGSP. HbA1c Assay Interferences 2017 [Available from: http://www.ngsp.org/interf.asp.Google Scholar
  28. 28.
    Unnikrishnan R, Anjana RM, Mohan V. Drugs affecting HbA1c levels. Indian J Endocrinol Metab. 2012;16(4):528–31.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Herman WH, Ma Y, Uwaifo G, Haffner S, Kahn SE, Horton ES, et al. Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the diabetes prevention program. Diabetes Care. 2007;30(10):2453–7.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Herman WH, Dungan KM, Wolffenbuttel BH, Buse JB, Fahrbach JL, Jiang H, et al. Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab. 2009;94(5):1689–94.CrossRefPubMedGoogle Scholar
  31. 31.
    Cohen RM. A1C: does one size fit all? Diabetes Care. 2007;30(10):2756–8.CrossRefPubMedGoogle Scholar
  32. 32.
    Eberhardt MS, Lackland DT, Wheeler FC, German RR, Teutsch SM. Is race related to glycemic control? An assessment of glycosylated hemoglobin in two South Carolina communities. J Clin Epidemiol. 1994;47(10):1181–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Gould BJ, Davie SJ, Yudkin JS. Investigation of the mechanism underlying the variability of glycated haemoglobin in non-diabetic subjects not related to glycaemia. Clin Chim Acta. 1997;260(1):49–64.CrossRefPubMedGoogle Scholar
  34. 34.
    Pani LN, Korenda L, Meigs JB, Driver C, Chamany S, Fox CS, et al. Effect of aging on A1C levels in individuals without diabetes: evidence from the Framingham offspring study and the National Health and nutrition examination survey 2001-2004. Diabetes Care. 2008;31(10):1991–6.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Nowicka P, Santoro N, Liu H, Lartaud D, Shaw MM, Goldberg R, et al. Utility of hemoglobin a(1c) for diagnosing prediabetes and diabetes in obese children and adolescents. Diabetes Care. 2011;34(6):1306–11.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    • Ehehalt S, Wiegand S, Korner A, Schweizer R, Liesenkotter KP, Partsch CJ, et al. Diabetes screening in overweight and obese children and adolescents: choosing the right test. Eur J Pediatr. 2017;176(1):89–97. This multicenter observational study of nearly 5,000 overweight and obese youth found that the optimal threshold for identifying diabetes using HbA1c was 6.0%, lower than suggested by current standards. CrossRefPubMedGoogle Scholar
  37. 37.
    Lee JM, Wu EL, Tarini B, Herman WH, Yoon E. Diagnosis of diabetes using hemoglobin A1c: should recommendations in adults be extrapolated to adolescents? J Pediatr. 2011;158(6):947–52 e1–3.CrossRefPubMedGoogle Scholar
  38. 38.
    Rohlfing CL, Little RR, Wiedmeyer HM, England JD, Madsen R, Harris MI, et al. Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U.S. population. Diabetes Care. 2000;23(2):187–91.CrossRefPubMedGoogle Scholar
  39. 39.
    Selvin E, Steffes MW, Gregg E, Brancati FL, Coresh J. Performance of A1C for the classification and prediction of diabetes. Diabetes Care. 2011;34(1):84–9.CrossRefPubMedGoogle Scholar
  40. 40.
    Brar PC, Mengwall L, Franklin BH, Fierman AH. Screening obese children and adolescents for prediabetes and/or type 2 diabetes in pediatric practices: a validation study. Clin Pediatr. 2014;53:771–776.Google Scholar
  41. 41.
    Li P, Jiang R, Li L, Li L, Wang Z, Li X, et al. Diagnostic performance of hemoglobin A1c for prediabetes and association with cardiometabolic risk factors in Chinese adolescents without diabetes. J Investig Med. 2012;60(6):888–94.CrossRefPubMedGoogle Scholar
  42. 42.
    Tomita M, Kabeya Y, Okada K, Shirai M, Asai S, Katsuki T, et al. Normal glucose tolerance with high HbA1c levels observed in two cases of Hb variants. Diabetol Int. 2010;1(2):104–7.CrossRefGoogle Scholar
  43. 43.
    Arakaki RF, Changcharoen B. Glycemic assessment in a patient with HB Leiden and type 2 diabetes. AACE Clin Case Rep. 2016;2(4):e307-e10.Google Scholar
  44. 44.
    Lee JM, Eason A, Nelson C, Kazzi NG, Cowan AE, Tarini BA. Screening practices for identifying type 2 diabetes in adolescents. J Adolesc Health. 2014;54(2):139–43.CrossRefPubMedGoogle Scholar
  45. 45.
    Wu EL, Kazzi NG, Lee JM. Cost-effectiveness of screening strategies for identifying pediatric diabetes mellitus and dysglycemia. JAMA Pediatr. 2013;167(1):32–9.CrossRefPubMedGoogle Scholar
  46. 46.
    Lee JM, Gebremariam A, Wu EL, LaRose J, Gurney JG. Evaluation of nonfasting tests to screen for childhood and adolescent dysglycemia. Diabetes Care. 2011;34(12):2597–602.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    McGill JB, Cole TG, Nowatzke W, Houghton S, Ammirati EB, Gautille T, et al. Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. trial of the GlycoMark assay. Diabetes Care. 2004;27(8):1859–65.CrossRefPubMedGoogle Scholar
  48. 48.
    Selvin E, Francis LM, Ballantyne CM, Hoogeveen RC, Coresh J, Brancati FL, et al. Nontraditional markers of glycemia: associations with microvascular conditions. Diabetes Care. 2011;34(4):960–7.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Chan CL, Pyle L, Kelsey M, Newnes L, Zeitler PS, Nadeau KJ. Screening for type 2 diabetes and prediabetes in obese youth: evaluating alternate markers of glycemia—1,5-anhydroglucitol, fructosamine, and glycated albumin. Pediatr Diabetes. 2016;17(3):206–11.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Endocrinology and DiabetesThe Children’s Hospital of PhiladelphiaPhiladelphiaUSA
  2. 2.University of MichiganAnn ArborUSA

Personalised recommendations